Abstract
Context Roux-en-Y gastric bypass (RYGB) has deleterious effects on bone mass, microarchitecture, and strength. Data are lacking on the skeletal effects of sleeve gastrectomy (SG), now the most commonly performed bariatric surgical procedure.
Objective We examined changes in bone turnover, areal and volumetric bone mineral density (aBMD, vBMD), and appendicular bone microarchitecture and estimated strength after SG. We compared the results to those previously reported after RYGB, hypothesizing lesser effects after SG than RYGB.
Design, Setting, Participants Prospective observational cohort study of 54 adults with obesity undergoing SG at an academic center.
Main Outcome Measure(s) Skeletal characterization with biochemical markers of bone turnover, dual-energy X-ray absorptiometry (DXA), quantitative computed tomography (QCT), and high-resolution peripheral QCT (HR-pQCT) was performed preoperatively and 6- and 12-months postoperatively.
Results Over 12 months, mean percentage weight loss was 28.8%. Bone turnover marker levels increased, and total hip aBMD decreased −8.0% (95% CI −9.1%, −6.7%, p<0.01). Spinal aBMD and vBMD declines were larger in postmenopausal women than men. Tibial and radial trabecular and cortical microstructure worsened, as did tibial estimated strength, particularly in postmenopausal women. When compared to data from a RYGB cohort with identical design and measurements, some SG biochemical, vBMD, and radial microstructural parameters were smaller, while other changes were not.
Conclusions Bone mass, microstructure, and strength decrease after SG. Some skeletal parameters change less after SG than after RYGB, while for others, we find no evidence for smaller effects after SG. Postmenopausal women may be at highest risk of skeletal consequences after SG.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Calcium citrate supplements were donated by Bariatric Advantage for the submitted work; ALS has received investigator-initiated research funding from Amgen and grant support from Bone Health Technologies; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, R01DK107629). Additional support came from a VA Career Development Award (1IK2CX000549) to ALS, the NIDDK grant P30DK098722, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS, P30AR075055), the National Center for Advancing Translational Sciences (UL1TR001872), and the Northern California Institute for Research and Education. KCW has received support from the Department of Veterans Affairs and the NIDDK (T32DK007418). TYK is supported by a VA Career Development Award (1IK2CX001984). Calcium citrate supplements were donated by Bariatric Advantage. Manuscript content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Protocol approval was obtained from the Institutional Review Board at the University of California, San Francisco.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Competing Interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Calcium citrate supplements were donated by Bariatric Advantage for the submitted work; ALS has received investigator-initiated research funding from Amgen and grant support from Bone Health Technologies; no other relationships or activities that could appear to have influenced the submitted work.
Funding: This study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, R01DK107629). Additional support came from a VA Career Development Award (1IK2CX000549) to ALS, the NIDDK grant P30DK098722, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS, P30AR075055), the National Center for Advancing Translational Sciences (UL1TR001872), and the Northern California Institute for Research and Education. KCW has received support from the Department of Veterans Affairs and the NIDDK (T32DK007418). TYK is supported by a VA Career Development Award (1IK2CX001984). Calcium citrate supplements were donated by Bariatric Advantage. Manuscript content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Data Availability: All data produced in the present study are available upon reasonable request to the authors.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
